Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.

Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, Chen M, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J.

Cancer Discov. 2018 Jun 8. pii: CD-17-1246. doi: 10.1158/2159-8290.CD-17-1246. [Epub ahead of print]

PMID:
29884728
2.

What is the role of nephrectomy following complete response to checkpoint inhibitors?

Woldu SL, Brugarolas J, Kapur P, Margulis V.

Urol Case Rep. 2018 Mar 14;18:60-63. doi: 10.1016/j.eucr.2018.02.016. eCollection 2018 May. No abstract available.

3.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 May 7. pii: S1078-1439(18)30126-1. doi: 10.1016/j.urolonc.2018.04.004. [Epub ahead of print]

PMID:
29748098
4.

Left ventricular outflow tract pseudoaneurysm diagnosed with point-of-care ultrasound in the emergency department.

Kapur P, Baimel M, Chenkin J.

CJEM. 2018 Mar 16:1-4. doi: 10.1017/cem.2018.20. [Epub ahead of print]

PMID:
29547367
5.

Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer.

Kittler R, Shiang C, Hutchinson R, Kollipara RK, Kapur P, Franto F, Lotan Y.

Oncotarget. 2018 Jan 6;9(10):9415-9424. doi: 10.18632/oncotarget.24072. eCollection 2018 Feb 6.

6.

EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Chen KS, Fustino NJ, Shukla AA, Stroup EK, Budhipramono A, Ateek C, Stuart SH, Yamaguchi K, Kapur P, Frazier AL, Lum L, Looijenga LHJ, Laetsch TW, Rakheja D, Amatruda JF.

Mol Cancer Ther. 2018 May;17(5):1079-1089. doi: 10.1158/1535-7163.MCT-17-0137. Epub 2018 Feb 26.

PMID:
29483210
7.

Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome-Not Quite "Burned Out".

Freifeld Y, Kapur P, Chitkara R, Lee F, Khemani P, Bagrodia A.

Front Neurol. 2018 Jan 30;9:20. doi: 10.3389/fneur.2018.00020. eCollection 2018.

8.

Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles: From Mice to Non-human Primates.

Xu J, Yu M, Peng C, Carter P, Tian J, Ning X, Zhou Q, Tu Q, Zhang G, Dao A, Jiang X, Kapur P, Hsieh JT, Zhao X, Liu P, Zheng J.

Angew Chem Int Ed Engl. 2018 Jan 2;57(1):266-271. doi: 10.1002/anie.201710584. Epub 2017 Dec 5.

PMID:
29160029
9.

Development of a Patient-specific Tumor Mold Using Magnetic Resonance Imaging and 3-Dimensional Printing Technology for Targeted Tissue Procurement and Radiomics Analysis of Renal Masses.

Dwivedi DK, Chatzinoff Y, Zhang Y, Yuan Q, Fulkerson M, Chopra R, Brugarolas J, Cadeddu JA, Kapur P, Pedrosa I.

Urology. 2018 Feb;112:209-214. doi: 10.1016/j.urology.2017.08.056. Epub 2017 Oct 19.

PMID:
29056576
10.

Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory.

Collins RRJ, Patel K, Putnam WC, Kapur P, Rakheja D.

Clin Chem. 2017 Dec;63(12):1812-1820. doi: 10.1373/clinchem.2016.267666. Epub 2017 Oct 16. Review.

PMID:
29038145
11.

Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.

Ho TH, Kapur P, Eckel-Passow JE, Christie A, Joseph RW, Serie DJ, Cheville JC, Thompson RH, Homayoun F, Panwar V, Brugarolas J, Parker AS.

J Clin Oncol. 2017 Nov 10;35(32):3706-3713. doi: 10.1200/JCO.2017.73.3238. Epub 2017 Oct 4.

12.

In Vivo X-ray Imaging of Transport of Renal Clearable Gold Nanoparticles in the Kidneys.

Xu J, Yu M, Carter P, Hernandez E, Dang A, Kapur P, Hsieh JT, Zheng J.

Angew Chem Int Ed Engl. 2017 Oct 16;56(43):13356-13360. doi: 10.1002/anie.201707819. Epub 2017 Sep 25.

PMID:
28881491
13.

Adverse drug reaction monitoring during antimicrobial therapy for septicemia patients at a university hospital in New Delhi.

Alam MS, Pillai KK, Abdi SAH, Kapur P, Pillai PK, Nagarajan K.

Korean J Intern Med. 2017 Sep 6. doi: 10.3904/kjim.2016.001. [Epub ahead of print]

14.

Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.

Zhang Y, Udayakumar D, Cai L, Hu Z, Kapur P, Kho EY, Pavía-Jiménez A, Fulkerson M, de Leon AD, Yuan Q, Dimitrov IE, Yokoo T, Ye J, Mitsche MA, Kim H, McDonald JG, Xi Y, Madhuranthakam AJ, Dwivedi DK, Lenkinski RE, Cadeddu JA, Margulis V, Brugarolas J, DeBerardinis RJ, Pedrosa I.

JCI Insight. 2017 Aug 3;2(15). pii: 94278. doi: 10.1172/jci.insight.94278. [Epub ahead of print]

15.

Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

Wang B, Lo UG, Wu K, Kapur P, Liu X, Huang J, Chen W, Hernandez E, Santoyo J, Ma SH, Pong RC, He D, Cheng YQ, Hsieh JT.

Int J Cancer. 2017 Nov 15;141(10):2121-2130. doi: 10.1002/ijc.30893. Epub 2017 Jul 31.

PMID:
28722220
16.

Splenic Involvement in Disseminated Mycobacterium avium-intracellulare Infection: Magnetic Resonance Imaging Findings.

Clark H, Khatri G, Kapur P, Pedrosa I.

J Comput Assist Tomogr. 2018 Jan/Feb;42(1):151-154. doi: 10.1097/RCT.0000000000000639.

PMID:
28708727
17.

Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma.

Xi Y, Yuan Q, Zhang Y, Madhuranthakam AJ, Fulkerson M, Margulis V, Brugarolas J, Kapur P, Cadeddu JA, Pedrosa I.

Eur Radiol. 2018 Jan;28(1):124-132. doi: 10.1007/s00330-017-4925-6. Epub 2017 Jul 5.

PMID:
28681074
18.

Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.

Gu YF, Cohn S, Christie A, McKenzie T, Wolff N, Do QN, Madhuranthakam AJ, Pedrosa I, Wang T, Dey A, Busslinger M, Xie XJ, Hammer RE, McKay RM, Kapur P, Brugarolas J.

Cancer Discov. 2017 Aug;7(8):900-917. doi: 10.1158/2159-8290.CD-17-0292. Epub 2017 May 4.

PMID:
28473526
19.

PBRM1 loss is a late event during the development of cholangiocarcinoma.

Luchini C, Robertson SA, Hong SM, Felsenstein M, Anders RA, Pea A, Nottegar A, Veronese N, He J, Weiss MJ, Capelli P, Scarpa A, Argani P, Kapur P, Wood LD.

Histopathology. 2017 Sep;71(3):375-382. doi: 10.1111/his.13234. Epub 2017 Jun 22.

PMID:
28394406
20.

Improved Magnetic Resonance Imaging-Pathology Correlation With Imaging-Derived, 3D-Printed, Patient-Specific Whole-Mount Molds of the Prostate.

Costa DN, Chatzinoff Y, Passoni NM, Kapur P, Roehrborn CG, Xi Y, Rofsky NM, Torrealba J, Francis F, Futch C, Hagens P, Notgrass H, Otero-Muinelo S, Pedrosa I, Chopra R.

Invest Radiol. 2017 Sep;52(9):507-513. doi: 10.1097/RLI.0000000000000372.

PMID:
28379863
21.

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS.

BMC Urol. 2017 Mar 21;17(1):19. doi: 10.1186/s12894-017-0209-3.

22.

Low Testosterone Levels Result in Decreased Periurethral Vascularity via an Androgen Receptor-mediated Process: Pilot Study in Urethral Stricture Tissue.

Hofer MD, Kapur P, Cordon BH, Hamoun F, Russell D, Scott JM, Roehrborn CG, Morey AF.

Urology. 2017 Jul;105:175-180. doi: 10.1016/j.urology.2017.02.037. Epub 2017 Mar 2.

PMID:
28263822
23.

Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients.

Ali Khan R, Kapur P, Jain A, Farah F, Bhandari U.

Ther Clin Risk Manag. 2017 Feb 20;13:139-149. doi: 10.2147/TCRM.S124621. eCollection 2017.

24.

Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer.

Bowman IA, Pedrosa I, Kapur P, Brugarolas J.

Clin Genitourin Cancer. 2017 Aug;15(4):e675-e680. doi: 10.1016/j.clgc.2017.01.026. Epub 2017 Feb 6.

PMID:
28258962
25.

Unusual skull tumors with psammomatoid bodies: a diagnostic challenge.

Richardson TE, Georgescu MM, Kapur P, Hwang H, Barnett SL, Raisanen JM, Cai C, Hatanpaa KJ.

Clin Neuropathol. 2017 May/Jun;36 (2017)(3):114-120. doi: 10.5414/NP300997. Review.

PMID:
28128725
26.

Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma.

Haddad AQ, Luo JH, Krabbe LM, Darwish O, Gayed B, Youssef R, Kapur P, Rakheja D, Lotan Y, Sagalowsky A, Margulis V.

BJU Int. 2017 May;119(5):741-747. doi: 10.1111/bju.13776. Epub 2017 Feb 9.

27.

Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer.

Mani RS, Amin MA, Li X, Kalyana-Sundaram S, Veeneman BA, Wang L, Ghosh A, Aslam A, Ramanand SG, Rabquer BJ, Kimura W, Tran M, Cao X, Roychowdhury S, Dhanasekaran SM, Palanisamy N, Sadek HA, Kapur P, Koch AE, Chinnaiyan AM.

Cell Rep. 2016 Dec 6;17(10):2620-2631. doi: 10.1016/j.celrep.2016.11.019.

28.

Targeting renal cell carcinoma with a HIF-2 antagonist.

Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J.

Nature. 2016 Nov 3;539(7627):112-117. doi: 10.1038/nature19796. Epub 2016 Sep 5.

29.

Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.

Passoni N, Gayed B, Kapur P, Sagalowsky AI, Shariat SF, Lotan Y.

Urol Oncol. 2016 Nov;34(11):485.e7-485.e14. doi: 10.1016/j.urolonc.2016.05.014. Epub 2016 Sep 13.

PMID:
27637323
30.

Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate.

Clavijo Jordan MV, Lo ST, Chen S, Preihs C, Chirayil S, Zhang S, Kapur P, Li WH, De Leon-Rodriguez LM, Lubag AJ, Rofsky NM, Sherry AD.

Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5464-71. doi: 10.1073/pnas.1609450113. Epub 2016 Aug 25.

31.

Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned.

Gayed BA, Youssef R, Darwish O, Kapur P, Bagrodia A, Brugarolas J, Raj G, DiMaio JM, Sagalowsky A, Margulis V.

BMC Urol. 2016 Jul 19;16(1):43. doi: 10.1186/s12894-016-0157-3.

32.

Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study.

Passoni NM, Shariat SF, Bagrodia A, Francis F, Rachakonda V, Xylinas E, Kapur P, Sagalowsky AI, Lotan Y.

Bladder Cancer. 2016 Jan 7;2(1):91-99.

33.

Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment.

Clark DG, McLaughlin PM, Woo E, Hwang K, Hurtz S, Ramirez L, Eastman J, Dukes RM, Kapur P, DeRamus TP, Apostolova LG.

Alzheimers Dement (Amst). 2016 Feb 15;2:113-22. doi: 10.1016/j.dadm.2016.02.001. eCollection 2016.

34.

Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract.

Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ.

Urology. 2016 Aug;94:314.e1-7. doi: 10.1016/j.urology.2016.05.030. Epub 2016 May 20.

35.

Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity.

Yuan Q, Kapur P, Zhang Y, Xi Y, Carvo I, Signoretti S, Dimitrov IE, Cadeddu JA, Margulis V, Brugarolas J, Madhuranthakam AJ, Pedrosa I.

Clin Genitourin Cancer. 2016 Dec;14(6):e585-e594. doi: 10.1016/j.clgc.2016.04.007. Epub 2016 Apr 22.

36.

Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.

Wang ZR, Wei JH, Zhou JC, Haddad A, Zhao LY, Kapur P, Wu KJ, Wang B, Yu YH, Liao B, He DL, Chen W, Margulis V, Hsieh JT, Luo JH.

Oncotarget. 2016 May 24;7(21):31508-19. doi: 10.18632/oncotarget.8971.

37.

The spectrum of renal cell carcinoma in adults.

Ananthakrishnan L, Kapur P, Leyendecker JR.

Abdom Radiol (NY). 2016 Jun;41(6):1052-65. doi: 10.1007/s00261-016-0737-4. Review.

PMID:
27108133
38.

Detecting positive surgical margins: utilisation of light-reflectance spectroscopy on ex vivo prostate specimens.

Lay AH, Wang X, Morgan MS, Kapur P, Liu H, Roehrborn CG, Cadeddu JA.

BJU Int. 2016 Dec;118(6):885-889. doi: 10.1111/bju.13503. Epub 2016 May 20.

39.

Balantidium Coli liver abscess: first case report from India.

Kapur P, Das AK, Kapur PR, Dudeja M.

J Parasit Dis. 2016 Mar;40(1):138-40. doi: 10.1007/s12639-014-0464-0. Epub 2014 Apr 26.

40.

Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

Zhou J, Luo J, Wu K, Yun EJ, Kapur P, Pong RC, Du Y, Wang B, Authement C, Hernandez E, Yang J, Xiao G, Cha TL, Wu HC, Wu D, Margulis V, Lotan Y, Brugarolas J, He D, Hsieh JT.

Oncogene. 2016 Sep 1;35(35):4663-74. doi: 10.1038/onc.2016.4. Epub 2016 Feb 15.

PMID:
26876207
41.
42.

Noninvasive Staging of Kidney Dysfunction Enabled by Renal-Clearable Luminescent Gold Nanoparticles.

Yu M, Zhou J, Du B, Ning X, Authement C, Gandee L, Kapur P, Hsieh JT, Zheng J.

Angew Chem Int Ed Engl. 2016 Feb 18;55(8):2787-91. doi: 10.1002/anie.201511148. Epub 2016 Jan 22.

43.

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death.

Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, Wang J, Castle EP, Stanton ML, Cheville JC, Jonasch E, Brugarolas J, Parker AS.

Mod Pathol. 2016 Jan;29(1):34-42. doi: 10.1038/modpathol.2015.123. Epub 2015 Oct 30.

44.

A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.

Wei JH, Haddad A, Wu KJ, Zhao HW, Kapur P, Zhang ZL, Zhao LY, Chen ZH, Zhou YY, Zhou JC, Wang B, Yu YH, Cai MY, Xie D, Liao B, Li CX, Li PX, Wang ZR, Zhou FJ, Shi L, Liu QZ, Gao ZL, He DL, Chen W, Hsieh JT, Li QZ, Margulis V, Luo JH.

Nat Commun. 2015 Oct 30;6:8699. doi: 10.1038/ncomms9699.

45.

Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy.

Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D.

Cancer Med. 2015 Dec;4(12):1844-52. doi: 10.1002/cam4.554. Epub 2015 Oct 16.

46.

Unsaturated Fatty Acids Stimulate Tumor Growth through Stabilization of β-Catenin.

Kim H, Rodriguez-Navas C, Kollipara RK, Kapur P, Pedrosa I, Brugarolas J, Kittler R, Ye J.

Cell Rep. 2015 Oct 20;13(3):495-503. doi: 10.1016/j.celrep.2015.09.010. Epub 2015 Oct 8.

47.

Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments.

Zhang Y, Kapur P, Yuan Q, Xi Y, Carvo I, Signoretti S, Dimitrov I, Cadeddu JA, Margulis V, Muradyan N, Brugarolas J, Madhuranthakam AJ, Pedrosa I.

Clin Genitourin Cancer. 2016 Feb;14(1):e25-36. doi: 10.1016/j.clgc.2015.08.007. Epub 2015 Aug 29.

48.

Light Reflectance Spectroscopy to Detect Positive Surgical Margins on Prostate Cancer Specimens.

Morgan MS, Lay AH, Wang X, Kapur P, Ozayar A, Sayah M, Zeng L, Liu H, Roehrborn CG, Cadeddu JA.

J Urol. 2016 Feb;195(2):479-83. doi: 10.1016/j.juro.2015.05.115. Epub 2015 Sep 26.

PMID:
26410735
49.

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J.

J Urol. 2016 Jan;195(1):180-7. doi: 10.1016/j.juro.2015.07.113. Epub 2015 Aug 20.

50.

High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.

Wolff NC, Pavía-Jiménez A, Tcheuyap VT, Alexander S, Vishwanath M, Christie A, Xie XJ, Williams NS, Kapur P, Posner B, McKay RM, Brugarolas J.

Oncotarget. 2015 Jul 10;6(19):16951-62.

Supplemental Content

Support Center